Company Overview
Arcturus Therapeutics Holdings Inc. operates as a messenger RNA medicines company dedicated to the development of therapeutics for rare diseases affecting the liver and respiratory systems. The company functions within the Healthcare sector and specifically the Biotechnology industry, where it leverages specialized technology platforms to advance gene therapies. Its operational scale is defined by a market capitalization of $200.67M and an annual revenue of $82.03M, supported by a workforce of 106 employees. These valuation and revenue figures indicate that the company is a small-cap entity with limited current revenue generation relative to its market valuation, reflecting the early-stage nature of its biotechnology development pipeline and the high capital requirements typical of the sector.
Financial Health
The company reported revenue of $82.03M over the trailing twelve months, yet it generated a net income of -$65,783,000, revealing a significant cost structure where expenses substantially exceed total revenue. This gap is further highlighted by an EBITDA of -$73,235,000, indicating that the business is not yet self-funding from operations and relies on external capital to cover research and development costs. Despite the negative earnings, the company maintains a free cash flow of $9.18M, which provides a degree of financial flexibility by allowing the firm to fund operations and development without immediate dilution or debt incurrence. However, the margins reflect the heavy cost burden inherent in pre-revenue or early-stage biotechnology companies, with a gross margin of -36.8%, an operating margin of -435.1%, and a profit margin of -80.2%. The negative gross margin specifically suggests that the cost of goods sold exceeds the revenue recognized, a common challenge in manufacturing complex mRNA therapeutics. On the balance sheet, the company holds $230.91M in cash against $25.00M in debt, resulting in a debt-to-equity ratio of 11.68, which presents a mixed picture of strong liquidity but high leverage relative to equity. This position is reinforced by a current ratio of 6.64, indicating robust short-term liquidity where current assets significantly outweigh current liabilities. The return on equity stands at -28.9% and the return on assets at -15.5%, metrics that reveal management is currently deploying capital to generate losses rather than profits, a typical characteristic of companies in the growth phase of the biotechnology lifecycle.
Valuation Assessment
Valuation metrics for the company show a trailing P/E ratio of N/A and a forward P/E of -1.68, implying that earnings are currently negative and that future earnings projections are not yet positive enough to support a traditional multiple. The absence of a positive trailing P/E suggests that the market is pricing the stock based on future potential rather than historical profitability. The price-to-book ratio is 0.94, indicating that the market values the company slightly below its book value, which often occurs with distressed or highly speculative biotechnology firms. Alternative valuation measures include a price-to-sales ratio of 2.45 and an EV/EBITDA of 0.07, suggesting that the stock is priced at a significant premium relative to its sales but has minimal enterprise value relative to earnings due to the near-zero earnings. The stock has experienced significant price volatility, trading between a 52-week high of $24.17 and a 52-week low of $5.85, with the current price trading at approximately 78.4% below the 52-week high. This wide range highlights the speculative nature of the investment, where the market price is highly sensitive to clinical trial results and regulatory approvals. The beta value is 2.49, meaning the stock is expected to be substantially more volatile than the broader market, amplifying both potential gains and losses during periods of market movement.
Growth & Income
The company experienced a revenue growth rate of -68.4% year-over-year, while earnings growth is listed as N/A due to negative historical earnings. The negative revenue growth indicates a contraction in sales, which could be attributed to the loss of specific revenue streams or a pause in commercialization activities. Since the earnings growth metric is N/A, it is impossible to determine if earnings are growing faster or slower than revenue, but the overall negative trajectory suggests a challenging operational period. Arcturus Therapeutics Holdings Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend distribution is typical for biotechnology firms that prioritize reinvesting all available earnings and cash reserves into research, development, and clinical trials to advance their therapeutic pipelines. Consequently, the overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, relying entirely on capital markets and existing cash reserves to fund future operations.